KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Assets: 2009-2024

Historic Assets for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $1.6 billion.

  • Novavax's Assets fell 31.10% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 31.10%. This contributed to the annual value of $1.6 billion for FY2024, which is 13.19% down from last year.
  • Novavax's Assets amounted to $1.6 billion in FY2024, which was down 13.19% from $1.8 billion recorded in FY2023.
  • Over the past 5 years, Novavax's Assets peaked at $2.6 billion during FY2021, and registered a low of $1.6 billion during FY2024.
  • For the 3-year period, Novavax's Assets averaged around $1.9 billion, with its median value being $1.8 billion (2023).
  • As far as peak fluctuations go, Novavax's Assets soared by 814.96% in 2020, and later declined by 20.42% in 2023.
  • Over the past 5 years, Novavax's Assets (Yearly) stood at $1.6 billion in 2020, then soared by 62.83% to $2.6 billion in 2021, then dropped by 12.34% to $2.3 billion in 2022, then declined by 20.42% to $1.8 billion in 2023, then decreased by 13.19% to $1.6 billion in 2024.